Reversal of Neuromuscular for Hip structure
Phase-Based Progress Estimates
Effectiveness
Safety
Cleveland Clinic, Cleveland, OH
Hip structure
Neostigmine - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The investigators propose a randomized trial comparing sugammadex and neostigmine for the reversal of neuromuscular blocks induced by rocuronium or vecuronium in adults having general anesthesia with muscular block for re-do hip and knee orthopedic surgery.
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Other trials for Hip structure
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 1 hour after surgery
1 hour after surgery
Complications related to urinary retention
Post-Void Bladder Volume
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Other trials for Hip structure
Trial Design
2 Treatment Groups
Reversal of Neuromuscular
1 of 2
Neuromuscular Block
1 of 2
Active Control
286 Total Participants · 2 Treatment Groups
Primary Treatment: Reversal of Neuromuscular · No Placebo Group · Phase 3
Reversal of NeuromuscularActiveComparator Group · 2 Interventions: Neostigmine, Sugammadex · Intervention Types: Drug, Drug
Neuromuscular Block
Drug
ActiveComparator Group · 1 Intervention: Neostigmine · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 hour after surgery
Closest Location: Cleveland Clinic · Cleveland, OH
2004First Recorded Clinical Trial
0 TrialsResearching Hip structure
972 CompletedClinical Trials
Who is running the clinical trial?
The Cleveland ClinicLead Sponsor
929 Previous Clinical Trials
1,388,635 Total Patients Enrolled
Daniel I Sessler, MDStudy ChairThe Cleveland Clinic
31 Previous Clinical Trials
113,893 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a ASA physical status of 1, 2, or 3.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments